Deciphera Pharmaceuticals Accounts Payable

Deciphera Pharmaceuticals (DCPH) currently reports a accounts payable of $19M as of March 2024. That compares with $20M in the prior-year period — down 1.1% year over year. Use the charts on this page to explore Deciphera Pharmaceuticals's accounts payable history and peer comparisons.

Deciphera Pharmaceuticals's accounts payable decreased from $20M to $19M — a 1.1% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Deciphera Pharmaceuticals reported $19M in accounts payable as of March 2024. That compares with $20M in the prior-year period — down 1.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $19M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Deciphera Pharmaceuticals, and consider following DCPH for alerts when major investors trade the stock.

Deciphera Pharmaceuticals is classified in the Healthcare sector. On accounts payable, it currently shows $19M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DCPH with unrelated industries.